DiaMedica Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that DiaMedica Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.62M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($7.70M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($7.70M) | Aug 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($7.71M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($7.71M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($7.71M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($6.27M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.12M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($5.12M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.15M) | May 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($5.15M) | Aug 12, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($5.15M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.47M) | Nov 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($4.48M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.48M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.27M) | May 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($5.27M) | Nov 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($5.27M) | Aug 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.06M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.36M) | Aug 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($9.03M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($8.01M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($8.14M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($6.88M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($5.64M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.74M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.16M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($4.74M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.52M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.13M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.36M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($3.54M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.42M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($3.37M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.62M) | May 4, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.32M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.71M) | Aug 11, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($2.40M) | May 5, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($2.66M) | Nov 4, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($2.74M) | Aug 11, 2020 |